CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
OPERATING EXPENSES
Research and development	$ 6,271,186	$ 6,394,534	$ 16,096,299	$ 20,063,752
Financing costs (Note 7)	1,527	3,145	5,821	10,996
General and administration	2,639,381	2,895,542	8,889,192	9,775,082
Total operating expenses	(8,912,094)	(9,293,221)	(24,991,312)	(29,849,830)
Foreign exchange	(827)	910	9,944	30,338
Interest and other income	1,614,048	417,872	3,881,974	974,207
Derivative liability gain		1,929	0	20,352
Loss for the period before taxes	(7,298,873)	(8,872,510)	(21,099,394)	(28,824,933)
Income tax recovery (expense)		45,767	(1,600)	45,667
Net loss for the period	(7,298,873)	(8,826,743)	(21,100,994)	(28,779,266)
OTHER COMPREHENSIVE LOSS
Unrealized gain (loss) on short-term investments (Note 4)	42,689	(2,951)	13,001	(51,682)
Loss and comprehensive loss for the period	$ (7,256,184)	$ (8,829,694)	$ (21,087,993)	$ (28,830,948)
Earnings Per Share [Abstract]
Basic loss per common share	$ (0.17)	$ (0.20)	$ (0.48)	$ (0.65)
Diluted loss per common share	$ (0.17)	$ (0.20)	$ (0.48)	$ (0.65)
Weighted average number of common shares outstanding - Basic	44,092,374	44,059,700	44,085,941	44,026,502
Weighted average number of common shares outstanding -Diluted	44,092,374	44,059,700	44,085,941	44,026,502